Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. Issue 4 (11th April 2019)

• Record Type: Journal Article
• Authors: Ho, Julie; Sharma, Atul; Kroeker, Kristine; Carroll, Robert; De Serres, Sacha; Gibson, Ian W; Hirt-Minkowski, Patricia; Jevnikar, Anthony; Kim, S Joseph; Knoll, Greg; Rush, David N; Wiebe, Chris; Nickerson, Peter
• Is Part Of: BMJ open. Volume 9:Issue 4(2019)
• Publication Date: 2019-04-11
• Subjects: urine CXCL10 -- subclinical rejection -- biomarker -- kidney transplant -- clinical trial; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-024908
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Subclinical inflammation is an important predictor of death-censored graft loss, and its treatment has been shown to improve graft outcomes. Urine CXCL10 outperforms standard post-transplant surveillance in observational studies, by detecting subclinical rejection and early clinical rejection before graft functional decline in kidney transplant recipients. Methods and analysis: This is a phase ii/iii multicentre, international randomised controlled parallel group trial to determine if the early treatment of rejection, as detected by urine CXCL10, will improve kidney allograft outcomes. Incident adult kidney transplant patients (n~420) will be enrolled to undergo routine urine CXCL10 monitoring postkidney transplant. Patients at high risk of rejection, defined as confirmed elevated urine CXCL10 level, will be randomised 1:1 stratified by centre (n=250). The intervention arm (n=125) will undergo a study biopsy to check for subclinical rejection and biopsy-proven rejection will be treated per protocol. The control arm (n=125) will undergo routine post-transplant monitoring. The primary outcome at 12 months is a composite of death-censored graft loss, clinical biopsy-proven acute rejection, de novo donor-specific antibody, inflammation in areas of interstitial fibrosis and tubular atrophy (Banff i-IFTA, chronic active T-cell mediated rejection) and subclinical tubulitis on 12-month surveillance biopsy. The secondary outcomes include decline of graft function, microvascular inflammation at 12 months, development of IFTA at 12 months, days from transplantation to clinical biopsy-proven rejection, albuminuria, EuroQol five-dimension five-level instrument, cost-effectiveness analysis of the urine CXCL10 monitoring strategy and the urine CXCL10 kinetics in response to rejection therapy. Ethics and dissemination: The study has been approved by the University of Manitoba Health Research Ethics Board (HS20861, B2017:076) and the local research ethics boards of participating centres. Recruitment commenced in March 2018 and results are expected to be published in 2023. De-identified data may be shared with other researchers according to international guidelines (International Committee of Medical Journal Editors [ICJME]). Trial registration number: NCT03206801; Pre-results.